# NCT06084481 (NCT06084481)

> Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06084481
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: AbbVie
- Conditions: Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer
- Interventions: ABBV-400; Itraconazole (ITZ); Bevacizumab
- Enrollment: 325
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Number of Participants with Adverse Events (AEs)
- Primary outcome: Maximum Observed Concentration (Cmax) of ABBV-400 Conjugate
- Primary outcome: AUC from Time 0 to the End of Dosing Interval (AUCtau) of ABBV-400 Conjugate

## Indexed commentary on NCT06084481 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06084481